Institutions Along With Private Equity Firms Who Hold Considerable Shares InQ32 Bio Inc. (NASDAQ:QTTB) Come Under Pressure; Lose 17% of Holdings Value
Positive Outlook for Q32 Bio: Buy Rating Backed by Promising Clinical Timelines and Increased Price Target
Q32 Bio Advances Clinical Trials Amidst Financial Challenges
Q32 Bio Inc Grapples With Internal Control Challenges Amid Compliance Costs
Express News | Q32 Bio Inc : Piper Sandler Raises Target Price to $85 From $60
Q32 Bio | 10-Q: Q3 2024 Earnings Report